NO20035458D0 - Virkestoffkombinasjon av for eksempel galantamin eller desoksypeganin og for eksempel acamprosat eller memantin for behandling av enavhengighet slik som alkoholisme - Google Patents

Virkestoffkombinasjon av for eksempel galantamin eller desoksypeganin og for eksempel acamprosat eller memantin for behandling av enavhengighet slik som alkoholisme

Info

Publication number
NO20035458D0
NO20035458D0 NO20035458A NO20035458A NO20035458D0 NO 20035458 D0 NO20035458 D0 NO 20035458D0 NO 20035458 A NO20035458 A NO 20035458A NO 20035458 A NO20035458 A NO 20035458A NO 20035458 D0 NO20035458 D0 NO 20035458D0
Authority
NO
Norway
Prior art keywords
deoxypeganine
acamprosate
galantamine
memantine
alcoholism
Prior art date
Application number
NO20035458A
Other languages
English (en)
Inventor
Joachim Moormann
Hermann Mucke
Klaus Opitz
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of NO20035458D0 publication Critical patent/NO20035458D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20035458A 2001-06-18 2003-12-08 Virkestoffkombinasjon av for eksempel galantamin eller desoksypeganin og for eksempel acamprosat eller memantin for behandling av enavhengighet slik som alkoholisme NO20035458D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
PCT/EP2002/006630 WO2002102388A2 (de) 2001-06-18 2002-06-15 Wirkstoffkombination von z.b. galanthamin oder desoxypeganin mit z.b. acamprosat oder memantin gegen sucht wie z.b. alkoholismus

Publications (1)

Publication Number Publication Date
NO20035458D0 true NO20035458D0 (no) 2003-12-08

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035458A NO20035458D0 (no) 2001-06-18 2003-12-08 Virkestoffkombinasjon av for eksempel galantamin eller desoksypeganin og for eksempel acamprosat eller memantin for behandling av enavhengighet slik som alkoholisme

Country Status (28)

Country Link
US (1) US20040192683A1 (no)
EP (1) EP1397138B1 (no)
JP (1) JP2005500298A (no)
KR (1) KR20040010744A (no)
CN (1) CN1527711A (no)
AR (1) AR034493A1 (no)
AT (1) ATE286397T1 (no)
AU (1) AU2002323873B2 (no)
BR (1) BR0211008A (no)
CA (1) CA2450787C (no)
CZ (1) CZ299951B6 (no)
DE (2) DE10129265A1 (no)
EA (1) EA006647B1 (no)
ES (1) ES2236551T3 (no)
HK (1) HK1063292A1 (no)
HU (1) HUP0400865A3 (no)
IL (2) IL159345A0 (no)
MX (1) MXPA03011825A (no)
MY (1) MY129726A (no)
NO (1) NO20035458D0 (no)
NZ (1) NZ529944A (no)
PL (1) PL367207A1 (no)
PT (1) PT1397138E (no)
SK (1) SK287180B6 (no)
TW (1) TWI325320B (no)
UA (1) UA76753C2 (no)
WO (1) WO2002102388A2 (no)
ZA (1) ZA200309232B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
PT1895994E (pt) * 2005-05-13 2010-12-03 Alza Corp Sistema de administração de medicamentos de camada múltipla com barreira contra o fluxo de material do reservatório
ATE547451T1 (de) 2005-09-01 2012-03-15 Mitsubishi Chem Corp Verfahren zur mehrstufigen festphasenpolykondensation von polyethylenterephthalat
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
PT2395990E (pt) 2009-02-12 2015-02-09 Univ Indiana Res & Tech Corp Material e métodos de tratamento de transtornos do desenvolvimento incluindo autismo comórbido e idiopático
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
WO2012050922A2 (en) * 2010-09-28 2012-04-19 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
KR102391511B1 (ko) * 2010-12-03 2022-04-26 오렉시젠 세러퓨틱스 인크. 날트렉손 요법에서 약물 생체이용률의 증가
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
TWI678202B (zh) * 2016-12-14 2019-12-01 陸汝斌 組合物用於製備治療酒癮或酒精濫用之藥物的用途
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (no) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
PT787115E (pt) * 1994-10-21 2000-05-31 Sanochemia Pharmazeutika Ag Processos para a preparacao de derivados de 4a,5,9,10,11,12-hexa-hidro-6h-benzofuro¬3a,3,2-ef|¬2|benzazepina
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
EP1071655A1 (en) * 1998-04-17 2001-01-31 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus

Also Published As

Publication number Publication date
SK287180B6 (sk) 2010-02-08
EA200400041A1 (ru) 2004-04-29
UA76753C2 (uk) 2006-09-15
CA2450787A1 (en) 2002-12-27
KR20040010744A (ko) 2004-01-31
EP1397138A2 (de) 2004-03-17
WO2002102388A3 (de) 2003-09-18
CZ299951B6 (cs) 2009-01-07
DE10129265A1 (de) 2003-01-02
PL367207A1 (en) 2005-02-21
MY129726A (en) 2007-04-30
EP1397138B1 (de) 2005-01-05
DE50201958D1 (de) 2005-02-10
NZ529944A (en) 2007-02-23
IL159345A0 (en) 2004-06-01
ATE286397T1 (de) 2005-01-15
HK1063292A1 (en) 2004-12-24
MXPA03011825A (es) 2005-03-07
CZ20033390A3 (en) 2004-03-17
PT1397138E (pt) 2005-04-29
CN1527711A (zh) 2004-09-08
ZA200309232B (en) 2004-07-21
BR0211008A (pt) 2004-10-26
HUP0400865A2 (hu) 2004-07-28
ES2236551T3 (es) 2005-07-16
IL159345A (en) 2009-02-11
CA2450787C (en) 2009-06-02
US20040192683A1 (en) 2004-09-30
SK15652003A3 (sk) 2004-04-06
EA006647B1 (ru) 2006-02-24
HUP0400865A3 (en) 2011-03-28
JP2005500298A (ja) 2005-01-06
WO2002102388A2 (de) 2002-12-27
AR034493A1 (es) 2004-02-25
TWI325320B (en) 2010-06-01
AU2002323873B2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
NO20035458D0 (no) Virkestoffkombinasjon av for eksempel galantamin eller desoksypeganin og for eksempel acamprosat eller memantin for behandling av enavhengighet slik som alkoholisme
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
HK1070053A1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
AU2002323873A1 (en) Active ingredient combination of E.G. galanthamine or deoxypeganine and E.G. acamprosate or memantine for treating an addiction such as alcoholism
IT1318524B1 (it) Composizioni a rilascio controllato contenenti un principio attivo,preferibilmente melatonina, e processo di preparazione delle stesse.
DK1441769T3 (da) Farmaceutiske formuleringer, der indeholder lave koncentrationer af peroxid, til behandling eller forebyggelse af vaginale infektioner
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
HUP0102362A2 (hu) Retard tabletta lineáris, vízben oldhatatlan poliszacharidokból
DE50207538D1 (de) Notverriegelungseinrichtung
PT1408035E (pt) Metodo de preparacao de derivativos de 1.5-diaril-3-trifluorometilo-delta2-pirazolinas que sejam racemicos e enanciomericamente puros
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
NO20040912L (no) Beskyttede 3,5-dihydroksy-2,2-dimetyl-valeroamider for syntese av epotiloner og derivater derav, og fremgangsmate for fremstilling og andvendelse derav.
NO20041878D0 (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
ITMI20020227A0 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
DK1490049T3 (da) Citalopram til behandling af forhöjet blodtryk
IT1317818B1 (it) Procedimento per la produzione di componenti per integratorialimentari, formulazioni dietetiche, cosmetiche e farmaceutiche,
NO20034273L (no) Steroidforbindelser, anvendelse av disse forbindelsene til fremstilling avmeioseregulerende medikamenter og fremgangsmåte for fremstillingav disse forbindelsene
RU2001113338A (ru) Препарат для лечения пчел
ITMI20011344A0 (it) Procedimento per la preparazione di 1,3-diossolan-2-oni

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application